Product Information
ROPINIROLE HCL 3 MG TABLET is a generic product labeled by Glenmark Pharmaceuticals Inc., USA, priced at $0.0768 per EA under NDC 68462025701. Its NADAC has been published 671 times since Nov 28, 2013.
FDA first approved this application on Feb 25, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
3 mg/1
Manufacturer
Glenmark Pharmaceuticals Inc., USANDC
68462025701
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
ROPINIROLE HYDROCHLORIDEApproval Type
Generic (ANDA)
FDA Application
ANDA090135FDA Approved
2/25/2010
TE Code
AB
On Market Since
2/25/2010
Pharmacological Classes
Price Statistics
The NADAC for ROPINIROLE HCL 3 MG TABLET has been published 671 times since Nov 28, 2013, and over the history we have for it it has declined 35.4%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.0768 per EA |
|---|---|
| All-time high | $0.1534 (Apr 16, 2014) |
| All-time low | $0.0575 (Nov 20, 2024) |
| 52-week high | $0.0848 |
| 52-week low | $0.0768 |
| Median price | $0.0943 |
| Average price | $0.0975 |
| Largest weekly change | +39.8% (Dec 19, 2018) |
| Weeks tracked | 671 |
| Tracking since | Nov 28, 2013 |
Generic Alternatives
The matcher finds 1 manufacturer offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Glenmark Pharmaceuticals Inc., USA manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
ropinirole market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Nonergot Dopamine Agonist class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of ROPINIROLE HCL 3 MG TABLET?
The current National Average Drug Acquisition Cost (NADAC) for ROPINIROLE HCL 3 MG TABLET, manufactured by Glenmark Pharmaceuticals Inc., USA, is $0.0768 per EA (NDC 68462025701), effective Sep 30, 2026.
How has the price of ROPINIROLE HCL 3 MG TABLET changed over time?
Over the history we have for it, the NADAC for ROPINIROLE HCL 3 MG TABLET has declined 35.4%. It has been tracked across 671 weekly CMS publications since Nov 28, 2013.
What are the highest and lowest recorded NADAC prices for ROPINIROLE HCL 3 MG TABLET?
Since Nov 28, 2013, the NADAC for ROPINIROLE HCL 3 MG TABLET has ranged from a low of $0.0575 (Nov 20, 2024) to a high of $0.1534 (Apr 16, 2014), with a median of $0.0943 per EA.
Are there cheaper alternatives to ROPINIROLE HCL 3 MG TABLET?
Yes. 1 manufacturer publishes a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, ROPINIROLE HCL 3 MG TABLET, is $0.0710 per EA — about 8% below ROPINIROLE HCL 3 MG TABLET.
Who manufactures ROPINIROLE HCL 3 MG TABLET?
ROPINIROLE HCL 3 MG TABLET (NDC 68462025701) is labeled by Glenmark Pharmaceuticals Inc., USA, and CMS classifies it as a generic product.